Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/40—Unsubstituted amino or imino radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Thiazole derivatives which are: a substituted 4- or 5-( ⁇ -aminoalkyl)thiazole with formula 1, wherein X represents a nitrogen atom and Y represents a sulphur atom or alternatively X represents a sulphur atom and Y represents a nitrogen atom, n is 1-6, R 1 represents a straight or branched alkyl group containing 1-4 carbon atoms and R 2 represents an amino group.
• the invention also relates to the acid addition salts of the compounds with the formula 1.
• Histamine receptors are classified according to the presentt knowledge into three categories which are described, mainly for historical reasons, with the qualifications of H 1 -, H 2 - and H 3 -receptor.
• Each of these classes of receptors presumably has its own and biologically specific function, in as far as they are present and dependent on the locating of such a receptor type in the organism involved.
• a treatment with endogenous or exogenous compounds may be necessary which may stimulate (agonistic activity) or inhibit (antagonistic activity) the receptor system.
• histamine H 2 -receptor (pharmacological) point of view, but also in therapeutic respect notably the stimulation of the histamine H 2 -receptor offers wide perspectives for the treatment of congestive heart diseases, accompanied by heart failure, and certain allergic disorders so that there exists a large interest from within the pharmaceutical industry for the development and application of selective, histamine H 2 -receptor active, compounds.
• the invention also relates to a process for the preparation of a ⁇ -aminoalkylthiazole derivative in which one prepares a histamine H 2 -receptor active compound.
• Certain alkylaminothiazoles are known from the literature. Examples are described in several patent applications, e.g. FR 76 24 496, US 26 36 037, GB 15 26 038 and GB 11 49 110. None of these patent applications reveal the now claimed compounds, whereas the method of preparation of the alkylaminothiazoles described in the aforementioned patent applications also differs from the process now claimed.
• Several authors have incidentally reported about examples of certain alkylamino-thiazoles: G.J. Durant et al describe in J.Med.Chem.
• the 2- amino-5-(2-aminoethyl)-4-methylthiazole (3) can be displaced competitatively by cimetidine, while the intrinsic activity (related to the chronotropic effect) is equal to that of histamine, thus rendering it to be a full agonist for the H 2 - receptor with an activity twice as high as that of histamine.
• the 2-amino-5-(3-aminopropyl)-4-methylthiazole (10b) is a full H 2 -receptor agonist with an activity 30 times as high as that of the corresponding 4(5)-3-aminopropyl)-imidazole.
• the 2-amino-5-(2-aminoethyl)-4-methylthiazole (3) shows however contrary to histamine (4), in the testing systems used not a single activity towards the E 1 and H 3 -receptors.
• the 4- or 5-( ⁇ -aminoalkyl) thiazole derivatives mentioned in the introduction with formula 1 may be obtained using a process not previously described in the literature in high yields by ring closure of a 3-bromo- ⁇ -phthalimidoalkan-2-one (8) with thiourea in dimethylformamide under mild conditions, followed by hydrazinolysis or hydrolysis with diluted hydrochloric acid of the resulting phthalimido derivatives (9) as depicted in reaction scheme A.
• the preparation of the 3-bromo- ⁇ -phthalimidoalkan-2-ones (8) as indicated in reaction scheme (A) takes place by selective bromination with bromine in carbon tetrachloride of the corresponding ⁇ -phthalimidoalkan-2-ones (7) which may be obtained according to a process described in the Dutch patent application 8800998.
• the necessary ⁇ -haloketones (6) which are to be used for the preparation of the 3-bromo- ⁇ -phthali- midoalkan-2-ones (8) are either commercially available or may be obtained in good yield according to a process described in the literature such as for example the process described in the Dutch patent application 65 11581.
• the invention also relates to a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formula 1 or an acid addition salt thereof.
• a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formula 1 or an acid addition salt thereof.
• Melting points were determined by a Mettler FP 5 device for the determination of melting points.
• Mass spectra are determined on a Varian Mat CH 5 spectrometer or on a Mat 90 (Finnigan Mat, San Jose, U.S.A.).
• 6-Bromo-2-hexanone (6a) is prepared according to a modified process as described in Dutch patent application 6511581 dated March 7,1966, cf. Chem. Abstr. 65, P20151d.
• a mixture of 552 g (4 mole) of particulated anhydrous potassium carbonate, 404 g (2 mole) of freshly distilled 1,3- dibromopropane, 260g (2 mole) of freshly distilled acetyl acetic ester and 700 ml of absolute ethanol is heated with vigorous stirring until circa 60°C. After the mild exothermal reaction beginning at circa 50°C, the reaction mixture is refluxed for circa 5 hours. After cooling the reaction mixture the inorganic salts are filtered off and the residue is rinsed with absolute ethanol. The combined filtrates are subsequently vacuum concentrated, thereafter to the residue circa 250 ml of demineralized water is added. Subsequently it is extracted with toluene. The collected toluene phases are combined, dried on anhydrous sodium sulfate, filtered and subsequently vacuum concentrated.
• Mass spectrum M/Z (intensity in %). 180(0.14): 178(0.11);
• the 4-phthalimido-2-butanone (7a) was prepared according to a modified process by H. Irai et al., Kogyo Kagaku
• the 5-phthalimido-2-pentanone (7a) is prepared according to Dutch patent application 8800998, April 18,1988.
• the 6-phthalimido-2-hexanone (7b) is prepared as described for the 5-phthalimido-2-pentanone (7a) in Dutch patent application 8800998, April 18,1988.
• Mass spectrum M/Z (intensity in %): 171(28.9); 154(75.1); 127(100); 115(9.7).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=19856444

Family Applications (2)

Family Applications Before (1)

Country Status (9)

Families Citing this family (1)

Citations (4)

Family Cites Families (3)

• 1990
  • 1990-01-19 NL NL9000132A patent/NL9000132A/nl not_active Application Discontinuation
• 1991
  • 1991-01-18 AU AU70644/91A patent/AU7064491A/en not_active Abandoned
  • 1991-01-18 CA CA002074180A patent/CA2074180A1/en not_active Abandoned
  • 1991-01-18 CA CA002074175A patent/CA2074175A1/en not_active Abandoned
  • 1991-01-18 JP JP3502574A patent/JPH05503096A/ja active Pending
  • 1991-01-18 EP EP91902804A patent/EP0511270A1/en not_active Withdrawn
  • 1991-01-18 IE IE017291A patent/IE910172A1/en unknown
  • 1991-01-18 WO PCT/NL1991/000008 patent/WO1991010657A1/en not_active Application Discontinuation
  • 1991-01-18 WO PCT/NL1991/000007 patent/WO1991010656A1/en not_active Application Discontinuation
  • 1991-01-18 IE IE017191A patent/IE910171A1/en unknown
  • 1991-01-18 AU AU70581/91A patent/AU7058191A/en not_active Abandoned
  • 1991-01-18 JP JP3502573A patent/JPH05503694A/ja active Pending
  • 1991-01-18 EP EP91902805A patent/EP0511271A1/en not_active Withdrawn
  • 1991-01-21 ZA ZA91418A patent/ZA91418B/xx unknown
  • 1991-01-21 ZA ZA91419A patent/ZA91419B/xx unknown
  • 1991-01-22 IL IL96998A patent/IL96998A0/xx unknown
  • 1991-01-22 IL IL96997A patent/IL96997A0/xx unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events